Together, they are furthering NuView Life Science’s mission: to change the way many types of cancer are diagnosed and treated using precision medicine technology. Diagnosing and treating cancer with a targeted, specific approach to the disease will help to increase positive patient outcomes while also driving down costs incurred by patients, healthcare providers, and third-party insurance payers.
Meet Our Management Team
He has served as Chief Medical Officer for multiple companies in this space including Genzyme Genetics, Lineagen, Rosetta Genomics, Generation Health, Helicos Biosciences, Good Start Genetics, Celula, Ambry Genetics, Alfigen. He has co-founded several successful ventures, and served as a consultant to a wide variety of entities ranging from large and small clinical laboratories, IVD and Biotech companies, investor groups, regulatory agencies, payers and legal firms.
In addition to clinical and technical expertise he has laboratory and general operational, business development, medical affairs/marketing and sales experience. He had formal training and both public and private sector experience in reimbursement and managed care. He has had international experience in Europe, Japan and China.
He is a graduate of Yale University and Albany Medical College and Board Certified in Pediatrics and Medical Genetics.
Currently he co-directs a novel reproductive genetics lab, Predictive Laboratories in Salt Lake City, and serves as a senior executive advisor to a number of start-ups and other clients. He serves on the Board of Directors and SAB of the TESS Foundation, a non-profit focused on treatments for epilepsy and symptoms of SLC13A5.
Mr. Davis has worked with a wide variety of clients in the areas of corporate, securities and business law since 1992 and has been responsible for over $1 billion in transactions. He is also on the Board of Directors of Theragene Pharmaceuticals, Inc. and Philter Labs, Inc., and was on the Board of Directors and Audit, Compensation, Nominating Committees (Chairman) and Special Committee (Chairman) of Telanetix, Inc., a publicly traded telecommunications company which was sold to InterMedia (an Oak Hill Capital portfolio company). He served as General Counsel and an executive officer of Molecular Imaging Corporation, a publicly traded healthcare company, and as in-house counsel for Leap Wireless International, a publicly traded wireless carrier. He also practiced in the Business and Corporate Group in the San Diego office of Luce, Forward, Hamilton & Scripps LLP (now Dentons), a large full-service law firm, where he advised both private and public clients in a variety of transactions.
Mr. Davis is licensed to practice law in California, the District of Columbia, and Minnesota. He received his Juris Doctor, Cum Laude, from the University of San Diego, School of Law in 1992. He received his B.A. in Political Science, Cum Laude, from Arizona State University in 1988.
He has also co-founded Clonatec, one of the first French biotech companies.